However, when Osimertinib was combined with Trametinib (MEK inhibitor), it displayed significantly enhanced potency, as evidenced by enhanced cleavage of caspase 3 and PARP (apoptotic markers) in EGFR-mutant NSCLC cells. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.